EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recompensation in Cirrhosis: Biomarkers and Strategies

Wagner Ramírez-Quesada, Edilmar Alvarado-Tapias, Sarah Shalaby, Virginia Hernández-Gea

Seminars in Liver Disease · 01.03.2025 · 45 (01) · 129-143

DOI: 10.1055/a-2542-9930 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, erschienen am 01.03.2025. Verfasst von Wagner Ramírez-Quesada und 3 weiteren Autor:innen. Beteiligte Einrichtung: Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Liver. Die Arbeit nennt 130 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The onset of decompensation in advanced chronic liver disease (ACLD) is a hallmark in natural history, with a poor prognosis and a significantly increased liver-related mortality. Etiological treatments for viral hepatitis or abstinence in cirrhosis due to alcohol abuse have demonstrated that some patients experience partial to complete clinical and analytical improvement, a stage termed “recompensation.” Although recompensation is primarily defined clinically based on treatable etiologies, it is still evolving for conditions like metabolic dysfunction-associated steatotic liver disease (MASLD). Despite the need for specific biomarkers in hepatic recompensation, no biomarkers have been thoroughly studied in this context. Biomarkers identified in compensated ACLD (cACLD) following etiological treatment might be explored for recompensation. Although the pathophysiology mechanisms underlying the hepatic recompensation remain unclear, understanding the mechanism involved in cirrhosis decompensation could help identify potential targets for recompensation. This review provides an update on the hepatic recompensation concept, examines the existing data on invasive and non-invasive biomarkers, mainly in cACLD after cure, that could be raised in recompensation, and explores future therapeutic targets for the hepatic recompensation process.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisLiverHumansBiomarkers

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Departament de Medicina i Ciències de la Salut, Fundació de Recerca Clínic Barcelona (FRCB-IDIBAPS), Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver), Universitat de Barcelo…
  • Centre for Biomedical Research in Liver and Digestive Diseases Network (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
  • Gastroenterology and Hepatology Department, Hospital Santa Creu i Sant Pau, Autonomus University of Barcelona, Barcelona, Spain.

Zitieren

APA

Ramírez-Quesada, W., Alvarado-Tapias, E., Shalaby, S., & Hernández-Gea, V. (2025). Recompensation in Cirrhosis: Biomarkers and Strategies. Seminars in Liver Disease, 45(01), 129-143. https://doi.org/10.1055/a-2542-9930

Vancouver

Ramírez-Quesada W, Alvarado-Tapias E, Shalaby S, Hernández-Gea V. Recompensation in Cirrhosis: Biomarkers and Strategies. Seminars in Liver Disease. 2025;45(01):129-143. doi:10.1055/a-2542-9930

BibTeX
@article{RamrezQuesada2025,
  author = {Ramírez-Quesada, Wagner and Alvarado-Tapias, Edilmar and Shalaby, Sarah and Hernández-Gea, Virginia},
  title = {Recompensation in Cirrhosis: Biomarkers and Strategies},
  journal = {Seminars in Liver Disease},
  year = {2025},
  volume = {45},
  number = {01},
  pages = {129--143},
  doi = {10.1055/a-2542-9930}
}
Kostenlos starten →